Madrigal Pharmaceuticals, Inc.
(NASDAQ : SNTA)

( )
SNTA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
100% secure: your email is never shared, and you may opt out at any time.
Loading SNTA News...
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
0.24%12.8214.2%$414.61m
SHPGShire PLC Sponsored ADR
-4.13%177.180.4%$199.93m
PRGOPerrigo Co. Plc
-2.64%69.956.4%$115.53m
PRXLPAREXEL International Corporation
0.86%80.217.9%$105.75m
ENDPEndo International Plc
1.78%13.128.9%$101.84m
MNKMallinckrodt Plc
5.66%43.3217.7%$98.33m
ALRAlere Inc.
-0.10%48.812.7%$84.33m
HZNPHorizon Pharma plc
2.31%10.207.6%$65.81m
JAZZJazz Pharmaceuticals Plc
-0.62%151.112.2%$58.85m
UTHRUnited Therapeutics Corporation
0.63%119.0813.9%$53.89m
MDCOMedicines Company
-0.64%39.1422.3%$49.60m
AERIAerie Pharmaceuticals, Inc.
3.04%55.909.3%$46.23m
ICPTIntercept Pharmaceuticals, Inc.
-2.70%112.1522.1%$38.93m
CTLTCatalent Inc
1.70%35.992.8%$36.68m
EGRXEagle Pharmaceuticals, Inc.
1.52%75.0122.6%$35.34m

Company Profile

Madrigal Pharmaceuticals, Inc. clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel compounds for the treatment of cardiovascular, metabolic and liver diseases. The company offers MGL-3196, an orally administered, small-molecule liver-directed ß-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Madrigal Pharmaceuticals was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.